What is the role of fluvoxamine in the treatment of COVID-19?

Updated: Jan 12, 2021
  • Author: Setu K Patolia, MD, MPH; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print


Fluvoxamine is a selective serotonin reuptake inhibitor. It has a strong affinity for the S1R receptor. It is an endoplasmic reticulum chaperone protein involved in the regulation of cytokine production. A double-blind placebo-controlled trial compared fluvoxamine with placebo in the outpatient treatment of patients with SARS-CoV2 infection on self-quarantine. Patients in the treatment arm received escalating doses of fluvoxamine. About 8% of patients in the placebo arm experienced clinical deterioration. The study has several limitations, such as small sample size (n=152), limited geographic involvement (subjects residing in the greater St. Louis area), loss of about 20% of the subject population to follow-up, and short follow-up duration. If fluvoxamine is proven to be effective in the treatment of COVID-19, further clarification on the exact mechanism of action is needed. [58]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!